• Contact
  • EPAD Academy
  • EPAD LCS Research Access
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
      • Project Deliverables
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • For Research Participants
    • Why Participate in EPAD?
      • EPAD & Dementia Research
      • Our Progress
    • Participation in EPAD Trials
    • EPAD Cohort Study
      • Trial Locations
      • EPAD Study Visits
    • EPAD Stories
    • Participation FAQs
  • For Intervention Owners
    • The EPAD Platform
      • Terms of Reference
    • EPAD Benefits
    • Clinical Candidate Selection
      • EPAD Application Process
    • EPAD FAQs
    • Research Resources
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Events
Menu back  

EPAD baseline data V500.0 published in the Journal of Prevention of Alzheimer’s disease

2019-11-27News

EPAD is pleased to announce the release of a new publication entitled “The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0” in the Journal of Prevention of Alzheimer’s disease. This paper describes the baseline data from the first 500 research participants (V500.0) to assist current and future researchers with their analysis. V500.0 has been collected, quality checked, released and is now available via secure online tools. To access the data, you will need to make an online request by following this link at http://www.ep-ad.org/erap where you will find a variety of resources to support your research.

 

Abstract:

BACKGROUND: The European Prevention of Alzheimer’s Dementia (EPAD) Programme is a pan-European project whose objective is to deliver a platform, adaptive, Phase 2 proof of concept (PoC) trial for the secondary prevention of Alzheimer’s dementia. A component of this platform is the Longitudinal Cohort Study (LCS) which acts as a readiness cohort for the PoC Trial as well as generating data for disease modelling work in the preclinical and prodromal phases of Alzheimer’s dementia.

OBJECTIVES: The first data wave has been collected, quality checked, released and now available for analysis to answer numerous research questions. Here we describe the results from key variables in the EPAD LCS with the objective of using these results to compliment analyses of these data in the future.

DESIGN: EPAD LCS is a cohort study whose primary objective is as a readiness cohort for the EPAD PoC Trial. As such recruitment is not capped at any particular number but will continue to facilitate delivery of the EPAD PoC Trial. Research Participants are seen annually (with an additional 6 month visit in the first year).

SETTING: The EPAD Trial Delivery Network comprises currently 21 centres across Europe.

PARTICIPANTS: Research participants are included if they are over 50 years old and do not have a diagnosis of dementia. Measurements: All research participants undergo multiple assessments to fully characterise the biology of Alzheimer’s disease and relate this to risk factors (both fixed and modifiable) and biomarker expression of disease through brain imaging, fluid samples (CSF, blood, urine and saliva), cognitive performance, functional abilities and neuropsychiatric symptomatology.

RESULTS: V500.0 represents the first 500 research participants baselined into EPAD LCS. The mean age was 66.4 (SD=6.7) and 47.8% were male. The data was split for presentation into 4 groups: [1] CDR=0 and Amyloid + (preclinical AD), [2] CDR=0 and Amyloid –, [3] CDR=0.5 and Amyloid + (prodromal AD) and [4] CDR=0.5 and Amyloid -.

CONCLUSIONS: The EPAD LCS is achieving its primary objective of trial readiness and the structured approach to data release as manifest by this first data release of V500.0 will assist researchers to describe and compare their findings as well as in systematic reviews and meta-analyses. It is anticipated given current recruitment rates that V1500.0 data release will take place in Autumn 2019. V500.1 (when the 1 year follow up is completed on the V500.0 (sub)cohort will be in Autumn 2019 also.

 

The open access article is available here: https://doi.org/10.14283/jpad.2019.46

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Spotlight on Fundació ACE
2019-11-29
The European Prevention of Alzheimer’s Dementia releases its first wave of data
2019-11-18
Interview with Laura Carrera Carballés
2019-11-04
Interview with Ross Dunne
2019-10-30
KNect365 webinar on EPAD is now available
2019-10-29
EPAD opens up its data access system to the entire research community
2019-10-25
Latest News
  • Spotlight on Fundació ACE
    2019-11-29
  • EPAD baseline data V500.0 published in the Journal of Prevention of Alzheimer’s disease
    2019-11-27
  • The European Prevention of Alzheimer’s Dementia releases its first wave of data
    2019-11-18
  • Interview with Laura Carrera Carballés
    2019-11-04
  • Interview with Ross Dunne
    2019-10-30
Subscribe to our Newsletter

View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

.@IMI_EPAD research participants are enthusiastic about the move to make their data available to researchers. "Research participants love and expect it - they want as much knowledge to be gained as possible from their contribution" said @craig_ritchie68 imi.europa.eu/news-events/ne… twitter.com/IMI_JU/status/…

reply retweet favorite
3:08 pm · 2019-12-12
Twitter
EPAD
EPAD
@IMI_EPAD

Baseline data from the first 500 research participants (V500.0) for the @IMI_EPAD Longitudinal Cohort Study are available. #datasharing #milestone #openscience More information on data availability here: bit.ly/EPAD_v500_0 pic.twitter.com/jZNmSwVj5R

reply retweet favorite
7:57 am · 2019-12-04
Twitter
EPAD
EPAD
@IMI_EPAD

“@IMI_EPAD is an innovative and highly ambitious project because it is based on the belief that we’ll get to preventively treat #Alzheimer's disease. This message aims to change the concept of prediction or #prevention to the concept of healing.”, said @MerceBoadaR @FundacioACE twitter.com/IMI_EPAD/statu…

reply retweet favorite
7:37 am · 2019-12-03
Twitter
EPAD
EPAD
@IMI_EPAD

Pleased to announce that Sheffield (UK) has recruited its first research participants in the @IMI_EPAD Longitudinal Cohort Study! EPAD has now 28 sites enrolling. Congratulations and well done to all involved! @IMI_JU @EFPIA @EU_H2020 pic.twitter.com/yBDQF9FU6S

reply retweet favorite
10:19 am · 2019-12-02
Twitter
EPAD
EPAD
@IMI_EPAD

We would love to catch up at #CTAD19 next week. Our #epadista Isabelle Carrie will be presenting an @IMI_EPAD poster. Come and visit us at Poster #5 twitter.com/IMI_EPAD/statu…

reply retweet favorite
2:10 pm · 2019-11-29
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Necessary Always Enabled